Notice NOT-HS-18-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MD-18-012 from the NIH Guide for Grants and Contracts. The purpose of the Research Centers in Minority Institutions (RCMI) Program is to expand the national capacity for research in the health sciences by providing cooperative agreement support to institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. The primary goals of the RCMI specialized centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of new and early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that will partner with the RCMI Institution.

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics & Genomics - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project London, England

Notice NOT-CA-18-107 from the NIH Guide for Grants and Contracts

Competitive : Rothamsted Research: We are seeking an enthusiastic Bioinformatics Scientist to contribute to a large cross-institute research program called Designing Future Wheat (DFW). AL5 2JQ, Harpenden

Graduate Programs- Masters's and PhD: Harvard Medical School, Department of Biomedical Informatics: Pursue graduate training to attain a Master of Biomedical Informatics or a PhD in Bioinformatics and Integrative Genomics at Harvard Medical School. Boston, Massachusetts

Graduate Programs- Masters's and PhD: Harvard Medical School, Department of Biomedical Informatics: Pursue graduate training to attain a Master of Biomedical Informatics or a PhD in Bioinformatics and Integrative Genomics at Harvard Medical School. Boston, Massachusetts

Funding Opportunity PA-18-928 from the NIH Guide for Grants and Contracts. The overarching goal of the Small Business Innovation Research (SBIR) program is to support small businesses to develop technologies that can advance the mission of the National Institute of Mental Health (NIMH), through research priorities identified by the Division of AIDS Research. This funding opportunity announcement encourages SBIR grant applications to support the development of new technologies for HIV prevention or treatment or the application of existing technologies to behavioral and social science HIV research in these domains.

Funding Opportunity PA-18-927 from the NIH Guide for Grants and Contracts. The overarching goal of the Small Business Technology Transfer (STTR) program is to support small businesses to develop technologies that can advance the mission of the National Institute of Mental Health, through the identified research priorities of Division of AIDS Research. This funding opportunity announcement encourages STTR grant applications to support the development of new technologies for HIV prevention or treatment or the application of existing technologies to behavioral and social science HIV research in these domains.

Funding Opportunity RFA-DA-19-016 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis. The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these deaths must be in rural communities). States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline.

Funding Opportunity RFA-DA-19-017 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse(NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these must be from rural communities) . States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline .

Funding Opportunity RFA-NS-18-046 from the NIH Guide for Grants and Contracts. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials. Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice.

Funding Opportunity RFA-NS-18-042 from the NIH Guide for Grants and Contracts. This R21 NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects. These studies may involve considerable risk but may lead to a breakthrough in a pain treatment.

Funding Opportunity RFA-NS-18-043 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

Education commensurate with a PhD (Microbiology, Molecular Biology, Bioprocessing, Food Science, or related discipline) or an MS or BS with a minimum of 5 years...
From DuPont - Wed, 19 Sep 2018 08:57:19 GMT - View all Madison, WI jobs

Funding Opportunity RFA-DE-19-005 from the NIH Guide for Grants and Contracts. The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years

Funding Opportunity RFA-DA-19-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to leverage SAMHSA funding (including TI-18-016, TI-18-015, and TI 17-014) for tribal responses to the opioid crisis by supporting culturally relevant research built upon projects supported by SAMHSA. The topic of the research project will vary depending on how funding is used in tribal communities. Potential topics include, for example, studies of evidence-based interventions adapted to enhance their feasibility, acceptability, availability and/or effectiveness in tribal communities; assessing the effectiveness of interventions with an evidence base from another population when implemented to address the opioid crisis in tribal communities; augmenting hypothesis-based data collection to inform intervention adaptation and implementation; or epidemiologic studies that assess the reach or implementation of interventions. Research supported through this FOA will be performed in two phases. The first phase (R61) will provide support for up to two years and allow for development and start up of the project including, where relevant, development and pilot testing of study elements including measurements, the study design, and/or adaption of intervention. This phase will identify and meet pre-specified milestones ensuring that the results of this phase inform and provide a foundation for the second phase of the research. Phase two (R33) is dependent upon successful completion of the R61 phase and an approved plan for the R33 phase. Phase two will provide possible funding for three years to expand to a full test of the research aims.

Funding Opportunity PA-18-926 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support eligible postdoctoral scientists maintain high productivity in an NIAID-funded laboratory while engaging in primary caregiver responsibilities. This program will provide administrative supplements to existing NIAID research grants to hire a full-time or part-time laboratory technician to work with the postdoctoral scientist on their project. Administrative supplements must support work within the scope of the original project.

Funding Opportunity RFA-MH-19-510 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide clues to novel intervention targets for alleviating some of the burden associated with these symptoms, or suggest optimal prevention strategies.

Funding Opportunity RFA-MH-19-511 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviatesomeburden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD RFA-MH-19-510 uses the R01 grant mechanism, whileRFA-MH-19-511 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.